MedTrace Logo

A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)

NCT04192591 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2026-05-07

No results posted yet for this study

Summary

To compile real-world outcomes of the Superion™ IDS in routine clinical practice.

Conditions

  • Lumbar Spinal Stenosis

Interventions

DEVICE

Superion™ IDS device

The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Natalie Bloom Lyons · Boston Scientific Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2038-02-28
Completion
2041-02-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04192591 on ClinicalTrials.gov